Active concurrent malignancy (except non melanoma skin cancer or carcinoma in situ of the cervix) or life threatening disease. If there is a history of prior malignancies or life threatening diseases, the patient must be disease free for at least years. Subjects must not have had prior systemic therapy except for localized emergency radiation to sites of life-threatening or function-threatening disease and/or no more than cycle of chemotherapy per a low or intermediate risk neuroblastoma regimen (as per P, A, ANBL, or similar) prior to determination of MYCN amplification status and histology. Patients must not be at short term risk for life threatening complications (such as airway compromise or bleeding from locoregional or metastatic disease,). EXCLUSION CRITERIA FOR SECOND-LINE THERAPY: Life-threatening visceral disease or other severe concurrent disease EXCLUSION CRITERIA FOR THIRD-LINE THERAPY: Life-threatening visceral disease or other severe concurrent disease Other serious or life-threatening conditions deemed unacceptable by the principal investigator History of life threatening or recurrent thrombosis/embolism; patients may participate if they are on anticoagulation during the treatment No active, second potentially life-threatening cancer Evidence of immediate life-threatening disease or a life expectancy of less than months Uncontrolled active life-threatening infection. Current or history of ventricular or life-threatening arrhythmias or diagnosis of long-QT syndrome Known intolerance to or life threatening side effects resulting from prior checkpoint inhibitor therapy Active life-threatening infection Life-threatening visceral disease or other severe concurrent disease Patient has malignancy or life-threatening systemic disease or a history of advanced, serious, life-threatening malignancy/disease within the last years, except very low-risk prostate cancer Active life-threatening infection Has an active concurrent malignancy/life-threatening disease. If there is a history of prior malignancies/life-threatening diseases, the subject is to be disease free for at least years. Subjects with other prior malignancies less than years before study entry may still be enrolled if they have received treatment resulting in complete resolution of the cancer and currently have no clinical, radiologic, or laboratory evidence of active or recurrent disease. Subjects will not be excluded for recurrent NMIBC, basal or squamous cell skin cancers, or noninvasive cancer of the cervix. Patients with an impending, life-threatening cerebral herniation syndrome, based on the assessment of the study neurosurgeon Active life-threatening infection Patients with an impending, life-threatening cerebral herniation syndrome, based on the assessment of the study neurosurgeons or their designate Patients with significant autoimmune disease that is active or potentially life threatening if activated Has an uncontrolled, life-threatening active infection No clinical evidence of life-threatening infection Patients with untreated or uncontrolled life-threatening infection Active life-threatening infection Patients must not have untreated or uncontrolled life-threatening infection No life threatening parenchymal disease or rapidly progressing disease warranting cytotoxic chemotherapy Patients with advanced/metastatic, symptomatic, visceral spread, at risk of life-threatening complications in the short term by investigator assessment Active life-threatening infection Patients with a history of life-threatening autoimmune disease Unstable or life-threatening arrhythmia Active life-threatening infection Significant extrahepatic disease representing an imminent life-threatening outcome Active life-threatening cancer requiring treatment other than ALL Active life-threatening autoimmune disease MATCHED RELATED DONOR: No history of life-threatening opportunistic infection HAPLOIDENTICAL RELATED DONOR: No history of life-threatening opportunistic infection Active life-threatening infection Life-threatening visceral disease or other severe concurrent disease No life- or organ-threatening manifestations of MCD Active life-threatening infection Severe life, threatening infection Severe life, threatening infection Significant extrahepatic disease representing an imminent life-threatening outcome HAPLOIDENTICAL RELATED DONOR: No history of life-threatening opportunistic infections Active life-threatening infection Significant extrahepatic disease representing an imminent life-threatening outcome Significant extrahepatic disease representing an imminent life threatening outcome Patients with an uncontrolled life-threatening infection Advanced/metastatic, symptomatic, visceral spread, with a risk of life-threatening complications in the short term. Patients with life-threatening condition or complication other than their basic condition Known life-threatening systemic disease Evidence of immediately life-threatening disease, progressively fatal disease, or life expectancy of months or less (eg, moribund or with shock unresponsive to fluid replacement) Life-threatening visceral disease or other severe concurrent disease Unstable or life-threatening arrhythmia Life-threatening visceral disease or other severe concurrent disease Life-threatening, visceral metastases Presence of any life-threatening co-morbidity Presence of any life-threatening co-morbidity Patients with immediately life-threatening visceral disease, for whom chemotherapy is the preferred treatment option. Current or history of ventricular or life-threatening arrhythmias or diagnosis of long-QT syndrome An active, second potentially life-threatening cancer Patients with advanced, symptomatic, visceral spread that are at risk of life threatening complication in the short term Patients with advanced, symptomatic, visceral spread that are at risk of life threatening complication in the short term Active life-threatening infection Subjects with advanced/metastatic, symptomatic, visceral spread, that are at risk of life-threatening complications in the short term including subjects with massive uncontrolled effusions, pulmonary lymphangitis, and over % of liver involvement in metastases. Immediately life-threatening, severe complications of leukemia. Patient has an active concurrent malignancy/life-threatening disease. If there is a history of prior malignancies/life-threatening diseases, the patient is to be disease free for at least years. Patients with other prior malignancies less than years before study entry may still be enrolled if they have received treatment resulting in complete resolution of the cancer and currently have no clinical, radiologic, or laboratory evidence of active or recurrent disease. Patients must not have untreated or uncontrolled life-threatening infection Patients with significant autoimmune disease that is active or potentially life threatening if activated Participants must not have life-threatening co-morbidities Patients with a history of life-threatening autoimmune disease Active life-threatening infection Life-threatening visceral disease or other severe concurrent disease Patients with an impending, life-threatening cerebral herniation syndrome, based on the assessment of the study neurosurgeons, Allan Friedman, John Sampson, or Peter Fecci, or their designate, will be excluded Any subject who has a life-threatening condition that requires high-dose immunosuppressant(s) Extensive symptomatic visceral disease including hepatic involvement and pulmonary lymphangitic spread of tumor, or disease that is considered by the investigator to be rapidly progressing or life threatening (eg, subjects who are intended for chemotherapy) Other serious or life-threatening conditions deemed unacceptable by the principal investigator Rapidly progressive, symptomatic, visceral spread of disease placing participant at risk of life-threatening complications in the short term Patients must not have untreated or uncontrolled life-threatening infection History of life threatening or recurrent thrombosis/embolism; subjects may participate if they are adequately anticoagulated during the treatment No untreated or uncontrolled life-threatening infection Severe or life-threatening infection within weeks of entry onto the study Patients with an uncontrolled life-threatening infection Life-threatening visceral disease or other severe concurrent disease Evidence of immediately life-threatening disease, progressively fatal disease, or life expectancy of months or less. Uncontrolled life-threatening infections Any life-threatening condition that could affect protocol compliance. Subject has an active, uncontrolled systemic infection considered opportunistic, life-threatening, or clinically significant at the time of treatment. Life-threatening visceral disease or other severe concurrent disease Disease that is considered by the investigator to be rapidly progressing or life threatening such as extensive symptomatic visceral disease including hepatic involvement and pulmonary lymphangitic spread of tumour (subjects who are intended for urgent chemotherapy) Evidence of life-threatening or fulminant CDAD. Serious and potentially life-threatening arrhythmia. Patients must have had no prior systemic therapy except for localized emergency radiation to sites of life-threatening or function-threatening disease and/or no more than cycle of chemotherapy per low- or intermediate-risk neuroblastoma therapy (P, A, ANBL) prior to determination of MYCN amplification and histology Life-threatening, visceral metastases History of life threatening or recurrent thrombosis/embolism; patients may participate if they are on anticoagulation during the treatment Subjects must be free of life-threatening illness (e.g., cancer) that would severely limit participation; those with chronic illnesses (e.g., asthma, diabetes) may participate with the permission of their physician Patients with immediately life-threatening visceral disease for whom chemotherapy is preferred treatment option. Have current or a history of ventricular or life-threatening arrhythmias or diagnosis Current metabolic or life-threatening disease life threatening allergic reaction to food and/or drugs Untreatable life-threatening arrhythmias Any other severe or life-threatening comorbidity that could increase the risk of bronchoscopic biopsy or ATV tunneling, for example: Acute life threatening infection Life-threatening metastatic visceral disease (defined as extensive hepatic involvement or symptomatic pulmonary lymphangitic spread).